
• Our Clinical Candidate VN-1032 is an orally-active, novel Selective Aryl Hydrocarbon Receptor Modulator (SAhRM) with significant efficacy as immunotherapy in pancreatic and colorectal cancer.
• Combines potent enhancement of intratumoral cytotoxic T cells with promising compatibility for PD-1 inhibitor combinations, while offering a pharmacological profile distinct from existing AhR antagonists.
• Vasculonics chemical platform modulates a critical molecular pathway implicated across multiple disease indications, including cancer immunotherapy and fibrotic diseases, positioning VN-1032 as a potentially transformative treatment approach.
2020: Vasculonics Incorporated as C-Corp
2019-21: SBIR Phase I Award
A Novel Disease Modifying Therapy for Progression of Pulmonary Arterial Hypertension
2020-21: SBIR Phase I Award
A Potential DDAH-Biotherapeutic to Preserve Kidney Function in Cardiac Surgery Patients
2020-21: NHILB Catalyze Award
Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension
2021: BARDA Blue Knight QuickFire Winner.
A Novel Small Molecule DDAH Modulator for Treatment of Diabetic Kidney Disease
2021-23: NHILB Catalyze II Award
Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension
2024: SBIR Phase II Award
Development of a Novel Disease Modifying Oral Therapy for Pulmonary Arterial Hypertension
2026: Vasculonics obtains FDA response to Pre-IND briefing

• AhR stimulates IDO expression in cancer cells leading to generation of AhR activator Kynurenine.
• AhR induces PDL1 and causes loss of effector function or exhaustion of CD8⁺ T-cells.
• AhR induces enrichment of Tregs in the tumor microenvironment which subsequently suppresses CD8⁺ T cell proliferation and cytotoxicity.
• AhR modulates macrophage and dendritic cell activities.
Therefore, modulation of these AhR mediated immune suppressive activities by VN-1032 within the tumor microenvironment is a key strategy to enhance immunotherapy efficacy.



• AhR is known to play important pathological roles in inflammatory and fibrotic diseases. AhR activation has been found essential for PAH progression in humans and animal models.
VN-1032 is a novel selective AhR modulator (SAhRM) that targets key mechanisms underlying inflammation, oxidative stress, and fibrosis, demonstrating disease-modifying efficacy in preclinical models of pulmonary arterial hypertension (PAH) and chronic kidney disease (CKD).

Jaipal Singh, PhD
CSO & Founder

Brad Lawson
CEO

Anantha Shekhar, MD, PhD
Co-Founder, SAB

Young Lee, PhD
Project Leader

Vijay Reddy, PhD, DABT
SVP, Toxicology

Raymond Kauffman, PhD
Pharmacology Advisor

Srinivas Kasibhatla, PhD
Chemistry Advisor

Douglas Balogh, PhD
FDA Regulatory Affairs / CMC Advisor

Timothy Frankel, MD
Scientific & Clinical Advisor, Oncology

Jamie Mills, MD, PhD
Clinical Investigator, PDAC

Andrew Dahlem, PhD
Strategic Advisor
1800 North Capitol Avenue, Noyes Pavilion 5th Floor, E504C, Indianapolis, Indiana 46202, United States